iShares Biotechnology ETF IBB

iShares Biotechnology ETF (el Fondo), anteriormente conocido como iShares Nasdaq Biotechnology Index Fund, es un fondo cotizado en bolsa (ETF). El Fondo busca resultados de inversión que correspondan generalmente al rendimiento del precio y el rendimiento del NASDAQ Biotechnology Index (el Índice). El Índice contiene valores de empresas listadas en NASDAQ que están clasificadas según el Industry Classification Benchmark como biotecnología o farmacéuticas, que también cumplen con otros criterios de elegibilidad determinados por NASDAQ. El Fondo invierte en una muestra representativa de valores incluidos en el Índice que colectivamente tienen un perfil de inversión similar al Índice. Debido al uso de muestreo representativo, el Fondo puede o no tener todos los valores incluidos en el Índice. El asesor de inversión del Fondo es BlackRock Fund Advisors, que es indirectamente propiedad de BlackRock, Inc.

Con 5 acciones de IBB (USD 1.036,83) habrías recibido USD 1,65 en dividendos en los últimos 12 meses.

IBB hizo una división de acciones (split) de 3:1 el 1 de diciembre de 2017: cada acción se convirtió en 3. Cambió la cantidad de acciones y su precio, pero no el valor total de la inversión.

• The Motley Fool 5 oct

  Better Healthcare ETF: Vanguard's Broad VHT vs. the iShares Biotechnology-Focused IBB

  The article compares two healthcare ETFs: Vanguard Health Care ETF (VHT) offers broad sector exposure with a low 0.09% expense ratio and 1.4% dividend yield, while iShares Biotechnology ETF (IBB) focuses on biotech with higher growth potential (49.8% 1-year return) but greater volatility and a 39.8% maximum drawdown. VHT is recommended for conservative investors seeking stability, while IBB suits high-risk growth investors.

  

• Zacks Investment Research 16 sept

  Should You Invest in the VanEck Biotech ETF (BBH)?

  The VanEck Biotech ETF (BBH) offers low-cost exposure to the biotech sector with a 0.35% expense ratio and $462.7 million in assets. The fund tracks the MVIS US Listed Biotech 25 Index and holds 26 companies with top holdings including Amgen, Gilead Sciences, and Vertex Pharmaceuticals. BBH has returned 21.89% year-to-date and 39.46% over the past year, but carries higher risk with a beta of 0.70 and 19.89% standard deviation. The fund received a Zacks ETF Rank of 2 (Buy).

  

• Zacks Investment Research 1 sept

  Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?

  The First Trust NYSE Arca Biotechnology ETF (FBT) is a passively managed fund offering broad exposure to the biotech sector with $2.91 billion in assets. The ETF has delivered strong performance with 29.36% gains year-to-date and 55.34% over the past year, though it carries higher risk with a beta of 0.66 and 20.71% standard deviation. With a 0.55% expense ratio and a Zacks ETF Rank of 2 (Buy), FBT is positioned as a solid option for biotech exposure, though larger competitors like IBB and XBI offer lower expense ratios.

  

• Zacks Investment Research 31 ago

  Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

  The article provides an in-depth analysis of the iShares Biotechnology ETF (IBB), a smart beta ETF with over $10.5 billion in assets that tracks the Nasdaq Biotechnology Index. With a 0.44% expense ratio and 252 holdings, IBB offers diversified exposure to biotechnology and pharmaceutical companies, though it carries higher risk with a beta of 0.70 and 20.59% standard deviation. The ETF returned 23.89% year-to-date and 51.48% over the past year as of August 2026, with top holdings including Amgen, Vertex Pharmaceuticals, and Gilead Sciences.

  

• The Motley Fool 12 jul

  Biotech ETFs: How Do FBT and IBB Match Up on Cost, Structure, and Performance?

  First Trust NYSE Arca Biotechnology Index Fund (FBT) and iShares Biotechnology ETF (IBB) offer different approaches to biotech sector exposure. FBT uses a concentrated 30-stock portfolio with higher returns (53.2% one-year, 168% ten-year) but greater risk, while IBB provides broader diversification with 248 holdings and lower fees (0.44% vs 0.55%). FBT has outperformed IBB over the past decade despite higher concentration risk.